Investment
Features
FeesSafety
Academy
More
Pluang+

Compare New York Times Co (NYT) vs Twist Bioscience Corp (TWST) Price & Performance

New York Times CoTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

New York Times Co vs Twist Bioscience Corp — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: New York Times Co is far larger — about 2.3× Twist Bioscience Corp's market cap, and New York Times Co pays a 1.21% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

NYTTWST
Market Cap
$12.29B$5.45B
Sector
MediaHealth
52-Week High
$85.86$102.88
52-Week Low
$51.43$24.16
Enterprise Value
$11.68B$5.37B
Dividend Yield
1.21%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

New York Times Co

The New York Times Company (NYSE: NYT) trades at $74.69, down 1.63% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $2.82 billion in 2025, with net income margin expanding to 12.17%. The stock is supported by strong cash flow from operations of $584 million and a consensus analyst price target of $78.00. Recent news includes the company's motion to quash subpoenas related to reporting on Air Force One, highlighting ongoing legal and press freedom challenges.

Outlook remains positive with consistent earnings growth and a defensive profile amid geopolitical tensions, but risks include regulatory pressures and competitive threats to digital subscriptions. The stock offers a dividend yield with the next payment scheduled for July 23, 2026. Institutional sentiment is mixed with a majority hold rating, suggesting cautious optimism for near-term appreciation toward the price target.

Twist Bioscience Corp

TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.

The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST